SEZARY SYNDROME
Clinical trials for SEZARY SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SEZARY SYNDROME trials appear
Sign up with your email to follow new studies for SEZARY SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat skin cancer
Disease control TerminatedThis early-phase trial tests two drugs, mogamulizumab and brentuximab vedotin, given together to people with a rare type of skin lymphoma (CTCL or mycosis fungoides) that has not responded to prior treatment. The main goal is to see if the combination is safe and to find the best…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo targets rare skin cancer in small trial
Disease control OngoingThis study tests whether combining pembrolizumab (an immunotherapy) with gemcitabine (a chemotherapy drug) can shrink tumors in people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. The trial enrolled 14 adults who had already tried at least one …
Matched conditions: SEZARY SYNDROME
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill shows promise for rare skin cancer in early trial
Disease control OngoingThis early-phase trial tests a new drug called tulmimetostat (DZR123) in 24 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. Participants must have tried at least one prior treatment. The study aims to see if the drug is safe and tolerable, …
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Matched conditions: SEZARY SYNDROME
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Engineered donor cells take aim at tough blood cancers in early trial
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…
Matched conditions: SEZARY SYNDROME
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC